pSivida (NASDAQ:PSDV; ASX:PVA) announced marketing approval in Poland for ILUVIEN for the treatment of vision impairment associated with diabetic macular edema (DME) considered insufficiently responsive to available therapies.
This latest approval means ILUVIEN is now approved in 17 European countries. ILUVIEN is currently being sold in the US, UK, Germany and Portugal.
pSivida is entitled to 20 per cent of net profits of ILUVIEN sales by its licensee on a country-by-country, quarter-by-quarter basis.
pSivida's pre-clinical research is focused on ocular and systemic delivery of biologics and drugs to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases.